Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Patient-Reported Outcomes and Medication Adherence in Patients with Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • E F Magavern
  • J C Kaski
  • R M Turner
  • H Drexel
  • A Janmohamed
  • A Scourfield
  • D Burrage
  • C N Floyd
  • E Adeyeye
  • J Tamargo
  • B S Lewis
  • Keld Per Kjeldsen
  • A Niessner
  • S Wassmann
  • P Sulzgruber
  • P Borry
  • S Agewall
  • A G Semb
  • G Savarese
  • M Pirmohamed
  • M J Caulfield
Vis graf over relationer

Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on PGx implementation. Clinical work force upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

OriginalsprogEngelsk
TidsskriftEuropean heart journal. Cardiovascular pharmacotherapy
ISSN2055-6837
DOI
StatusE-pub ahead of print - 31 aug. 2021

ID: 67446039